Oncología médica

2018

1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

   Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

2. A risk-adapted approach to patients with stage i seminoma according to the status of rete testis: The fourth Spanish germ cell cancer group study

   Oncology (Switzerland), Vol. 95, Núm. 1, pp. 8-12

3. Altered red blood cell membrane fatty acid profile in cancer patients

   Nutrients, Vol. 10, Núm. 12

4. Aportación del uso medicinal de los derivados del cannabis: una revisión de su potencial eficacia clínica y riesgos

   Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 115, Núm. 2, pp. 83-95

5. Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment

   Supportive Care in Cancer, Vol. 26, Núm. 12, pp. 4077-4086

6. Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: A systematic review

   Oncotarget, Vol. 9, Núm. 32, pp. 22850-22861

7. Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: Pooled analysis in 4 basque country university hospitals

   ClinicoEconomics and Outcomes Research, Vol. 10, pp. 189-199

8. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

   BMC Cancer, Vol. 18, Núm. 1

9. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

   JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308

10. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267

11. Contribution of the medicinal use of cannabis derivatives: A review of their potential clinical efficacy and risks

    Gaceta Medica de Bilbao, Vol. 115, Núm. 2, pp. 83-95

12. Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer

    Surgical Endoscopy, Vol. 32, Núm. 12, pp. 4912-4922

13. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/ HER2– advanced or metastatic breast cancer in Spain

    ClinicoEconomics and Outcomes Research, Vol. 10, pp. 773-790

14. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis

    Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264

15. Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii490

16. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536

17. Indirect costs associated with glioblastoma: Experience at one hospital

    Neurologia, Vol. 33, Núm. 2, pp. 121-128

18. Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke

    Journal of Stroke and Cerebrovascular Diseases, Vol. 27, Núm. 5, pp. e86-e87

19. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: Results of the observational “LORENA” study

    OncoTargets and Therapy, Vol. 11, pp. 5845-5852

20. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38